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The recent emergence and transmission of Neisseria gonorrhoeae isolates with reduced susceptibility to
expanded-spectrum cephalosporins such as cefixime and ceftriaxone have been reported. The aim of this study
was to determine the correlation of different polymorphisms in the penA, mtrR, porB1b (penB), and ponA genes
of N. gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. Eighteen gonococcal isolates with
reduced cefixime and ceftriaxone susceptibility (Cefi) and two susceptible isolates were characterized using
serovar determination, antibiograms, N. gonorrhoeae multiantigen sequence typing (NG-MAST), and sequenc-
ing of penA, mtrR, porB1b, and ponA alleles. For the Cefi isolates (n  18), the MICs of cefixime and ceftriaxone
ranged between 0.032 to 0.38 g/ml and 0.064 to 0.125 g/ml, respectively. These isolates were assigned five
different serovars and six divergent NG-MAST sequence types. Eleven isolates (61%) with higher MICs of
cefixime and ceftriaxone contained a nearly identical penA mosaic allele and previously described polymor-
phisms in mtrR (a single nucleotide [A] deletion in the promoter), penB (mutations in porB1b encoding loop
3 of PorB1b), and ponA (ponA1 polymorphism). The remaining seven Cefi isolates (39%), which had somewhat
lower MICs of cefixime and ceftriaxone, contained an aspartic acid insertion (Asp-345a) in PBP 2 in conjunc-
tion with alterations of 4 to 10 amino acid residues in the C-terminal region of the transpeptidase domain of
penA. In conclusion, an unambiguous association between penA mosaic alleles, in conjunction with genetic
polymorphisms in mtrR, porB1b, and ponA, and greater reduced susceptibility to cefixime and ceftriaxone was
identified.
Since the mid to late 1990s, the number of infections caused
by Neisseria gonorrhoeae, the etiologic agent of the sexually
transmitted infection gonorrhea, has increased in many West
European countries (11, 33). Resistance of N. gonorrhoeae to
traditional antimicrobial agents, e.g., penicillin and tetracy-
cline, in the 1980s led to discontinuation of their use in treating
gonococcal infections, and the more recent emergence of
strains resistant to currently prescribed antibiotics, such as
fluoroquinolones, azithromycin, and expanded-spectrum ceph-
alosporins, is now a serious concern worldwide (2, 5, 7, 14, 18,
24, 26). Presently, the recommended first-line treatments for
gonorrhea in most countries include antibiotics such as cef-
ixime, ceftriaxone, spectinomycin, and in some cases azithro-
mycin or ciprofloxacin. However, resistance to fluoroquino-
lones in many countries is high (e.g., 31% in Western Europe in
2004), resistance to azithromycin is rapidly increasing (18), and
resistance to spectinomycin was already reported in the 1980s
(4). Recently and most disquieting, the emergence of N. gonor-
rhoeae isolates with reduced susceptibility or resistance in vitro
to broad-spectrum oral cephalosporins such as cefixime and
parenteral cephalosporins such as ceftriaxone has been de-
scribed (1, 2, 16, 18, 24, 25, 30). In occasional cases, treatment
failures when using cefixime have been reported (6, 30).
Thorough antimicrobial susceptibility testing requires cul-
turing of N. gonorrhoeae. However, in some geographic areas
with high-prevalence populations, nucleic acid amplification
tests are rapidly replacing culture for diagnosis of gonorrhea.
Accordingly, comprehensive knowledge regarding the genetic
basis of reduced susceptibility and resistance to many antimi-
crobials and, subsequently, development of fast and objective
genetic assays for screening of resistance are crucial.
The genetic mechanisms of chromosomally mediated high-
level resistance to penicillin are complicated and multifaceted.
Stepwise transformation experiments using DNA from a resis-
tant strain to increase the resistance of a susceptible strain
demonstrate the involvement of mutated alleles of at least four
genes: penA, mtrR, porB1b (penB), and ponA. Moreover, these
polymorphisms are acquired in a particular order and often
increase resistance only when other mutated alleles are
present. Insertion of an aspartic acid codon (Asp-345a) in the
penA gene together with downstream mutations causes a re-
duced affinity of penicillins for penicillin-binding protein 2
(PBP 2) (8, 9). Specific mutations in the promoter or coding
segments of mtrR, which encodes the major transcriptional
repressor of the mtr locus, increase transcription of three tan-
demly linked genes in the mtrCDE operon encoding the MtrC-
MtrD-MtrE efflux pump (34). Increased levels of the efflux
pump confer resistance to multiple hydrophobic agents (i.e.,
crystal violet, Triton X-100, and erythromycin) and some hy-
drophilic antibiotics such as the penicillins (15). Nonsynony-
mous substitutions at two positions within the constriction loop
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of porB1b, i.e., penB mutations, decrease the permeability of
the outer membrane porin PorB1b for hydrophilic antimicro-
bials (13, 20, 21). Surprisingly, these mutations do not increase
resistance in the absence of an mtrR mutation, suggesting that
the MtrC-MtrD-MtrE efflux pump and PorB1b work together
to increase penicillin resistance by limiting the concentration
of the antibiotic in the periplasm (21). Additionally, a single
substitution in ponA (the ponA1 allele), which encodes an
altered PBP 1 with a reduced affinity for penicillin, contributes
to high-level penicillin resistance in N. gonorrhoeae (22). Fi-
nally, pilQ2 mutations (previously named penC) or a pilQ de-
letion increase penicillin resistance if the penA, mtrR, and penB
resistance determinants are present, presumably because PilQ
forms an outer membrane pore through which antimicrobials
diffuse into the periplasm (22, 35). However, the role of pilQ
mutations in clinical resistance to antimicrobials has not yet
been established.
The reduced susceptibility of N. gonorrhoeae strains to broad-
spectrum cephalosporins such as cefixime and ceftriaxone
has been proposed to be associated with polymorphisms in
several of these genes and especially with certain penA mosaic
alleles (1, 16, 24, 25, 31, 32). However, thorough knowledge
regarding these molecular mechanisms is still lacking. For ex-
ample, all these genes need to be systematically sequenced in
more numerous and evidently diverse clinical N. gonorrhoeae
strains with reduced susceptibility to broad-spectrum cephalo-
sporins, the cooperation of the genetic polymorphisms men-
tioned above needs to be comprehensively examined, and it is
crucial to investigate the contribution of specific polymor-
phisms in different regions of these genes as well as other
genetic loci to the MICs of divergent broad-spectrum cepha-
losporins. Thus, the aim of this study was to correlate different
polymorphisms in penA, mtrR, porB1b (penB), and ponA of N.
gonorrhoeae with reduced susceptibility to cefixime and ceftri-
axone.
MATERIALS AND METHODS
N. gonorrhoeae isolates. A total of 18 N. gonorrhoeae isolates with reduced
susceptibility to cefixime and/or ceftriaxone (referred to hereafter as Cefi) and,
for comparison, two additional clinical isolates susceptible to these cephalospo-
rins were examined (Table 1). In Sweden, the breakpoints used for cefixime and
ceftriaxone are MICs of 0.064 g/ml (susceptible) and 0.5 g/ml (resistant).
All isolates were received at the National Reference Laboratory for Pathogenic
Neisseria, Örebro University Hospital, Örebro, Sweden, from February 2002
through May 2005. The Cefi isolates included clinical isolates (n  10) from six
different gonorrhea patients in Sweden and clinical isolates provided in 2003 by
Catherine Ison, Health Protection Agency, United Kingdom (n  3), and Joan
Knapp, Centers for Disease Control and Prevention (n  5), for antimicrobial
susceptibility testing.
Phenotypic and genotypic characterization. -Lactamase production was an-
alyzed using nitrocefin discs, and the antibiotic susceptibility profiles (expressed
as MICs in g/ml) to cefixime, ceftriaxone, penicillin G, ciprofloxacin, azithro-
mycin, and spectinomycin were analyzed using the Etest method (AB Biodisk,
Solna, Sweden) as previously described (3).
Cultivation, serovar determination, isolation of genomic DNA, porB1b gene
sequencing, and N. gonorrhoeae multiantigen sequence typing (NG-MAST) were
performed as previously described (28, 29). The promoter and coding regions of
TABLE 1. Country of origin, serovar, antibiogram, NG-MAST, porB allele, and the polymorphisms in penA, mtrR, porB1b, and ponA alleles












119/04 Sweden IB-2 3 ST5 0.032 0.064 2.0 No D345a Deletion of A K101, D102 P421
158/04 Sweden IB-3 4 ST1724b 0.047 0.094 1.5 No D345a Deletion of A K101, D102 WT
188/03 United Kingdom IB-16 5 ST1619 0.064 0.064 1.0 No D345a WTc,d K101, D102 P421
201/03 United Kingdom IB-16 5 ST1619 0.064 0.064 1.0 No D345a WTd K101, D102 P421
253/04 Sweden IB-4 6 ST1723b 0.064 0.064 1.5 No D345a WTd D101, WT P421
273/04 Sweden IB-4 6 ST1723b 0.064 0.094 1.5 No D345a WTd D101, WT P421
196/03 United Kingdom IB-16 5 ST1619 0.094 0.094 1.0 No D345a WTd K101, D102 P421
66/02 Sweden IB-1 7 ST326 0.19 0.094 2.0 Yes Deletion of Ad K101, D102 P421
30/02 Sweden IB-1 7 ST326 0.25 0.094 3.0 Yes Deletion of Ad K101, D102 P421
64/02 Sweden IB-1 7 ST326 0.25 0.094 2.0 Yes Deletion of Ad K101, D102 P421
65/02 Sweden IB-1 7 ST326 0.25 0.094 1.5 Yes Deletion of Ad K101, D102 P421
67/02 Sweden IB-1 7 ST326 0.25 0.094 2.0 Yes Deletion of Ad K101, D102 P421
59/03 United States IB-1 8 ST925 0.25 0.094 6.0 Yes Deletion of A K101, D102 P421
66/03 United States IB-1 8 ST925 0.25 0.125 4.0 Yes Deletion of A K101, D102 P421
35/02 Sweden IB-1 7 ST326 0.38 0.094 2.0 Yes Deletion of Ad K101, D102 P421
82/03 United States IB-1 8 ST925 0.38 0.125 6.0 Yes Deletion of A K101, D102 P421
90/03 United States IB-1 8 ST925 0.38 0.125 6.0 Yes Deletion of A K101, D102 P421
91/03 United States IB-1 8 ST925 0.38 0.125 6.0 Yes Deletion of A K101, D102 P421
119/05h Sweden IB-23 1 ST1722b 0.016 0.002 0.012 WT WT WT, WT WT
128/05h Sweden IB-1 2 ST1580 0.016 0.002 0.008 WT WT WT, WT WT
a CFM, cefixime; CRO, ceftriaxone; PEN, penicillin G.
b STs not previously identified.
c WT, wild type.
d Contained the G453D amino acid replacement in the DNA-binding motif of MtrR, which also may increase the expression of the MtrCDE efflux pump (34), mainly
in strains lacking the dominant deletion of A in the promoter.
e The features of the 13-bp repeat in the promoter are indicated.
f Wild type: G101, A102.
g Wild type: L421.
h Isolates susceptible to cefixime and ceftriaxone.
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mtrR and ponA were amplified in a LightCycler real-time PCR system (Roche
Molecular Biochemicals, Mannheim, Germany) using previously described mtrR
(19) and ponA primers (22). Briefly, each PCR mixture (20 l) contained 2 l
LightCycler-FastStart DNA Master SYBR green I (Roche Diagnostics GmbH,
Mannheim, Germany), 3 mM MgCl2, 0.5 M of each primer, and 2 l of DNA
template. The parameters of the amplifications were as follows: an enzyme
activation step at 95°C for 10 min, followed by 40 sequential cycles of heating up
to 95°C, 49°C (mtrR) or 68°C (ponA) for 10 s, and 72°C for 37 s (mtrR) or 51 s
(ponA). The parameters of the subsequent melting curve analyses were as fol-
lows: heating the PCR products up to 95°C, cooling at 63°C (mtrR) or 74°C
(ponA) for 45 s, and finally slowly heating (0.1°C/s) up to 95°C.
Using two previously described primer pairs, PA2/B1 or B1/C2 (25), the penA
genes from all of the different isolates were amplified by PCR in a PTC-100
instrument (MJ Research, Watertown, MA). The PCR mixtures (50 l) con-
tained 1.25 U of AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster
City, CA), 1 PCR Gold buffer (Applied Biosystems), 2.5 mM MgCl2, 0.8 mM
deoxynucleoside triphosphates, 1 M of each primer, and 1 l of DNA template.
The following PCR amplification parameters were used: an enzyme activation
step at 94°C for 10 min, followed by 30 sequential cycles of 94°C for 1 min, 54°C
for 1 min, and 72°C for 2 min. At the end of the final cycle, an extension phase
of 72°C for 7 min was included. A positive control (DNA of N. gonorrhoeae
reference strain CCUG 15821) and a negative control (distilled water) were
included in each PCR run. The products were analyzed by gel electrophoresis as
previously described (28). All PCR products were stored at 4°C prior to purifi-
cation.
The PCR products were purified using a High Pure PCR product purification
kit (Roche Diagnostics GmbH, Mannheim, Germany) and sequenced using the
PCR primers mentioned above as previously described (28, 29). However, for
sequencing of the entire penA genes of divergent isolates, the primers B2 (25),
Gcup2, Fo, Ro, AA-1, and PenA-R2 (27) were also utilized. Multiple-sequence
alignments of nucleotide and amino acid sequences and phylogenetic analysis
using BioEdit (version 5.0.9) software and TREECON (version 1.3b) software,
respectively, were performed as previously described (29).
RESULTS
The origins of the isolates, results of serovar determinations
and genotyping, and antibiotic resistance profiles are summa-
rized in Table 1.
Phenotypic characterization. The Cefi isolates (n  18) were
assigned five different serovars. The ranges of MICs of cefixime
(0.032 to 0.38 g/ml), ceftriaxone (0.064 to 0.125 g/ml), and
penicillin G (1.0 to 6.0 g/ml) of all the Cefi isolates were
markedly higher than the MICs of the susceptible strains,
119/05 and 128/05 (Table 1). None of the isolates produced a
-lactamase.
Genotypic characterization. The Cefi isolates (n  18) com-
prised six divergent porB1b sequences and were assigned six
different NG-MAST sequence types (STs) (Table 1). The 18
Cefi isolates also comprised 11 divergent penA sequences.
However, 11 (61%) of these isolates displayed identical (n  4)
or highly similar (99.6% identity; n  7) penA alleles, which
comprised mosaic patterns from nucleotide 294 to the end of
the gene (Table 1). These penA mosaic alleles encoded three
slightly divergent amino acid sequences (Fig. 1). All of these
isolates also contained the three nonsynonymous nucleotide
substitutions, resulting in amino acid alterations G5453S,
I3123M, and V3163T, which have been proposed to be im-
portant for reduced susceptibility to cefixime according to data
from site-directed mutagenesis (24). These isolates also dis-
played the highest MICs of cefixime (range: 0.19 to 0.38 g/ml)
and ceftriaxone (range: 0.094 to 0.125 g/ml). The penA genes
from the remaining seven (39%) Cefi isolates harbored an
insertion of a single codon (GAC) encoding an aspartic acid
residue (D345a) in PBP 2 in conjunction with alterations of 4
to 10 amino acid residues in the C-terminal region of the
transpeptidase domain of penA. These isolates contained five
slightly divergent amino acid sequences (Fig. 1) and displayed
lower MICs to cefixime (range: 0.032 to 0.094 g/ml) and
ceftriaxone (range: 0.064 to 0.094 g/ml) (Table 1).
Seven (39%) of the Cefi isolates contained only a single
nucleotide (A) deletion in the 13-bp inverted repeat located
between the 10 and 35 sequences of the mtrR promoter, six
(33%) contained this A deletion in the promoter and in addi-
tion a G453D amino acid replacement in the DNA-binding
motif of MtrR, and five (28%) displayed only the G453D
amino acid replacement. Furthermore, 16 (89%) of the Cefi
isolates contained identical nonsynonymous nucleotide substi-
tutions resulting in alterations of both the amino acid residues
of PorB1b, G1013K and A1023D, which are known to be
important for phenotypic expression of penB resistance (13, 20,
21), while the two remaining Cefi isolates contained only a
G3D alteration in residue 101. Finally, 17 (94%) of the Cefi
isolates contained the ponA1 polymorphism, i.e., a single nu-
cleotide transition (T3C) causing one amino acid alteration
(L4213P) (Table 1). The penA, mtrR, porB1b, and ponA alleles
of the two ceftriaxone-susceptible isolates, which were in-
cluded for comparison, all comprised wild-type sequences (Ta-
ble 1).
DISCUSSION
In the present study, an unambiguous association between
penA mosaic alleles, but also genetic polymorphisms in mtrR,
porB1b (penB), and ponA, and reduced susceptibility to cef-
ixime and ceftriaxone was identified. This reduced suscepti-
bility is not due to -lactamase-encoding plasmids (present
study; see also references 1 and 25). In the present study, the
penA alleles displayed mosaic segments or other polymor-
phisms, such as a single codon insertion encoding D345a, in all
of the Cefi isolates. In addition, the main variant of the penA
mosaic alleles (61% of the Cefi isolates) was identical or nearly
identical to the penA mosaic alleles identified in N. gonorrhoeae
isolates with reduced susceptibility to cefixime and ceftriaxone
in Japan (1, 16, 24) and to ceftriaxone in Australia (31, 32).
According to the serovar determination, porB1b sequencing,
and NG-MAST, many of the Cefi isolates were indistinguish-
able or closely related, which has also been reported in previ-
ous studies using pulsed-field gel electrophoresis (16). In the
present study, all the Cefi isolates with penA mosaic alleles
were serovar IB-1 and ST326 or ST925, which are STs that
have previously been associated with penA mosaic alleles and
reduced susceptibility to ceftriaxone in Australia (31). Conse-
quently, these Cefi isolates may have emerged from a limited
number of strains and been subsequently disseminated in many
countries worldwide. However, more comprehensive data are
needed to support this idea, especially given the observation
that penA mosaic alleles were identified in isolates assigned
also five other STs in the Australian study (31), which instead
may suggest horizontal genetic exchange of the penA mosaic
sequences.
In concordance with previous studies, the main variant of
the penA mosaic alleles from the present study comprised
segments, especially in the transpeptidase domain, that were
identical or highly similar to the corresponding regions of penA
in commensal or other pathogenic Neisseria species such as N.
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perflava, N. sicca, N. cinerea, N. flavescens, and N. meningitidis
(data not shown) (1, 24, 25). Accordingly, this penA mosaic
allele may have evolved in vivo due to interspecies recombi-
nation of partial penA sequences from other Neisseria species.
In previous studies (1, 24), the importance of penA mosaic
alleles for reduced susceptibility to cefixime and ceftriaxone
was suggested by transformation in vitro of penA mosaic alleles
from donor isolates with reduced susceptibility to fully suscep-
tible recipients. However, although the MICs of the recipient
isolates were significantly increased, they still were substan-
tially lower than those of the donor isolates. In addition, in the
study by Takahata et al. (24), isolates with penA mosaic alleles
FIG. 1. Multiple-sequence alignment of the amino acid sequences of PBP 2 in Cefi strains of N. gonorrhoeae. One representative of each distinct
sequence variant associated with reduced susceptibility to cefixime and ceftriaxone in the present study is displayed (n  8). Dots denote identity
with the wild-type PBP 2 amino acid sequence of the N. gonorrhoeae strain LM306 (GenBank accession no. M32091), and dashes represent
alignment gaps due to insertions/deletions. The mosaic PBP 2 sequence of the N. gonorrhoeae strain NG-3 (GenBank accession no. AB071984),
which previously has been associated with reduced cefixime susceptibility (1), is also shown.
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showed only a fourfold increase in the MIC of ceftriaxone,
compared to a 16-fold increase in the MIC of cefixime. This
difference was suggested to be due to the long side chain at the
C-3 position of the cephem skeleton of ceftriaxone, which
might increase the affinity for the altered PBP 2. Overall, this
clearly indicates that polymorphisms in other genetic loci, e.g.,
mtrR, penB, and ponA, influence susceptibility to cefixime and
especially ceftriaxone. In the present study, all Cefi isolates
containing the main variant of penA mosaic alleles also con-
tained the previously described polymorphisms in mtrR, penB,
and ponA, and these strains were the ones with the highest
MICs of cephalosporins. These data provide further evidence
of a link between polymorphic penA alleles and the mtrR, penB,
and ponA alleles (see below) in the development of interme-
diate resistance to cefixime and ceftriaxone.
Of the 18 Cefi isolates, 72% contained the previously de-
scribed single nucleotide deletion in the mtrR promoter, which
results in the loss of expression of MtrR and, consequently,
enhanced expression of the MtrC-MtrD-MtrE efflux pump and
increased resistance to antibiotics, including -lactams, and
multiple hydrophobic agents. In addition, the remaining five
Cefi isolates contained a G453D amino acid replacement in
the DNA-binding motif of MtrR, which may also increase the
expression of the MtrCDE efflux pump (34), mainly in strains
lacking the dominant deletion of A in the promoter. These
genetic polymorphisms may explain why all of these Cefi iso-
lates also displayed an increased MIC of azithromycin (range:
0.125 to 0.5 g/ml) (34). Sixteen (89%) of the Cefi isolates also
contained alterations in amino acid residues 101 and 102 in
putative loop 3 of PorB1b (i.e., penB mutations), which reduce
the permeability of PorB1b to penicillin, cephalosporins, and
ciprofloxacin (17, 22). Interestingly, two relatively low-level
resistant isolates, 253/04 and 273/04, had only a G1013D mu-
tation in loop 3. The presence of a single aspartic acid at
position 101 was shown to provide only a partial increase in
penicillin and tetracycline resistance compared to that for a
G1013D/A1023D double mutation (13, 20, 21), and this may
explain in part the lower level of resistance in these strains.
Finally, all except one (94%) of the Cefi isolates contained the
ponA1 polymorphism that results in one amino acid alteration
(L4213P) in PBP 1, resulting in a decreased affinity for peni-
cillin that even in normal cases is approximately 10-fold lower
than that for PBP 2. This genetic polymorphism contributes to
high-level penicillin resistance by decreasing the acylation rate
of -lactam antimicrobials in PBP 1 by three- to fourfold (22).
It is important to point out that the polymorphic alleles
examined here (penA, mtrR, penB, and ponA) are necessary but
not sufficient for high-level resistance to penicillin (22). That is,
genetic studies have shown that transformation of a susceptible
strain to the same level of resistance as a high-level penicillin-
resistant strain with DNA from the resistant strain is exceed-
ingly difficult, if even possible, to achieve in vitro (8, 10, 22). In
conjunction with penA, mtrR, penB, and ponA, the pilQ2 mu-
tation was shown recently to confer the same level of penicillin
resistance (MIC  4 g/ml) in laboratory strains as in high-
level clinical isolates. However, it is unlikely that pilQ2, which
interferes with type IV pilus formation that is critical for patho-
genesis, is present in clinical isolates. Indeed, mutations in pilQ
arise spontaneously and have not been observed in any clinical
isolates examined thus far. Taken together, these data indicate
that there remains at least one unidentified resistance deter-
minant present in clinical isolates that is not transferable and,
along with penA, mtrR, penB, and ponA, helps strains achieve
high-level penicillin resistance.
In contrast to penicillin resistance, the roles of polymorphic
penA, mtrR, penB, and ponA alleles in increased MICs of ex-
panded-spectrum cephalosporins are mainly unknown. It is
clear that the mosaic penA alleles are critical for increased
cephalosporin resistance, but it has not yet been determined
which of the other polymorphic alleles are important and
whether an unidentified allele similar to the one responsible
for high-level penicillin resistance is involved. It is also impor-
tant to note that as yet no high-level cefixime- or ceftriaxone-
resistant strain (MIC  1 g/ml) has been reported. Conse-
quently, the maximum levels of MICs of these cephalosporins
that can be attained by solely divergent polymorphisms in these
genes, single locus and in cooperation, are unclear at the
present time. However, given the proclivity of the gonococcus
to become resistant to all previously prescribed antibiotics, it
may be more a matter of when and not if strains emerge that
are resistant to the currently prescribed cephalosporins.
A serious concern emerging from our study is that many of
the Cefi isolates comprise a multiantimicrobial-resistant phe-
notype (1, 19, 25). For example, 13 of the isolates (72%)
showed increased MICs of azithromycin (range: 0.125 to 0.5
g/ml), 17 (94%) were resistant to ciprofloxacin (range: 0.25 to
32 g/ml), and all 18 displayed a highly reduced susceptibility
to penicillin G (range: 1.0 to 6.0 g/ml). In contrast, all the
isolates were susceptible to spectinomycin (MIC range: 6 to 16
g/ml). Although resistance to spectinomycin is rare today, as
early as the 1980s widespread use of spectinomycin was shown
to rapidly increase the prevalence of resistance to this antimi-
crobial (4), possibly due to mutations in the 16S rRNA gene
(12).
In recent times, ciprofloxacin was the recommended first-
line treatment for gonorrhea in Sweden; however, resistance
to this antimicrobial has rapidly increased and ciprofloxacin
is no longer the first-line antibiotic of choice (23, 29). Pres-
ently, ceftriaxone (250-mg parenteral administration), cefixime
(400-mg oral administration), spectinomycin (2-g parenteral
administration), or in some more rare cases azithromycin (2-g
oral administration; e.g., for patients with concurrent chlamyd-
ial infection) are the recommended first-line treatments when
the results of antimicrobial susceptibility testing are not yet
known. Even though the emergence of Cefi isolates is currently
not a major clinical problem, as treatment failures using ceftri-
axone caused by resistance have not yet been reported, it is
critical to monitor the increasing MICs to expanded-spectrum
cephalosporins. Moreover, it will be important to elucidate the
genetic mechanisms that are responsible for decreased suscep-
tibility and future resistance. Overall, the present study high-
lights the importance of continuous local and national surveil-
lance of N. gonorrhoeae antimicrobial resistance in order to
reveal the emergence of new resistant strains, to monitor the
changing patterns of resistance, and to be able to update treat-
ment recommendations, including dose regimens, on a regular
basis to assure successful eradication of the bacteria and, con-
sequently, treatment of gonococcal infections.
In conclusion, we report an unambiguous association be-
tween particularly penA mosaic alleles but also genetic poly-
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morphisms in mtrR, penB, and ponA and reduced susceptibility
to cefixime and ceftriaxone. Further studies are needed to
unambiguously elucidate associations between polymorphisms
in these genes, and perhaps other genes, and reduced suscep-
tibility to newer, broad-spectrum cephalosporins.
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Örebro County, the Örebro University Hospital Research Foundation,
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